Board of Directors
Dr Jane Griffiths
Former Global Head of Actelion
Jane has enjoyed a long and successful career in the pharmaceutical sector at Johnson & Johnson. During her tenure there she held executive roles in clinical research, international and strategic marketing, product management and operational management. In her last role before retiring in December 2019, Jane was Global Head of Actelion, where she led the integration of the Swiss biotech business following its acquisition by Johnson & Johnson. Prior to that Jane had been Company Group Chair of Janssen EMEA, the group’s research based pharmaceutical arm. During her time with Johnson & Johnson, Jane led its Corporate Citizen Trust in EMEA and sponsored its Women’s Leadership Initiative. Jane was also sponsor of Janssen’s Global Pharmaceuticals Sustainability Council.
Currently, Jane is a Non-Executive Director of the FTSE 100 companies, Johnson Matthey plc, BAE Systems plc, and is a member of the board of directors of TB Alliance, a not-for-profit organisation dedicated to the delivery of affordable tuberculosis drugs. Jane is a past Chair of the European Federation of Pharmaceutical Industries and Associations, past Chairwoman of the PhRMA Europe Committee and former member of the Corporate Advisory Board of the UK Government backed ‘Your Life’ campaign, aimed at encouraging more people to study STEM subjects.
Chief Executive Officer
Experienced General Manager, former President of AstraZeneca UK
Appointed in 2018, Lisa Anson has led the transformation of Redx into a clinical stage biotech with two programmes in clinical development and a growing pipeline of preclinical assets. During this time the company also secured major partnership deals for four assets with large and speciality pharma and secured long term financing with new blue chip life science focused investors.
Prior to joining Redx, Lisa had significant leadership experience in global pharmaceuticals over a 20-year career at AstraZeneca plc with her appointment in 2012 as President of AstraZeneca UK having held a series of senior commercial leadership roles in the company both the US and the UK. Lisa is also a key player in the industry, and in 2018 she was elected to the Board of the Bio Industry Association (BIA). Previously Lisa has been President of the Association of the British Pharmaceutical Industry (ABPI) and member of the board, where she chaired several UK industry committees and worked closely with the UK Government. Lisa started her career as a management consultant in London before moving to California with a cancer disease management company,
Lisa holds an MBA (awarded with distinction) from INSEAD, France and a First-Class honours degree in Natural Sciences from Cambridge University in the UK. Lisa currently lives in Cheshire with her husband and three children.
Finance, Audit and Corporate Governance specialist with several high profile organisations
Peter Presland has nearly 45 years’ experience in business, much of that at the highest levels of management within both public and private companies. A law graduate at King’s College, London, he also qualified as a Chartered Accountant with Arthur Andersen. In 1980, he joined C E Heath plc, a major publicly quoted international insurance group, as Group Accountant/Treasurer and became in 1985 the youngest ever PLC Director when appointed Group Finance Director at the age of 34. He was promoted to become Heath’s Group Chief Executive in 1990, and in 1996, he devised the demerger of C E Heath’s computer services operations into a separate publicly listed company, Rebus Group plc, becoming its Chief Executive and in 1999 its Executive Chairman. Shareholders doubled their money in three years. Since 2001, Peter has pursued a portfolio non-executive career. These appointments include the Chairmanship in 2003 of LINK, the UK ATM network, where he led a major corporate governance change and completed the merger of LINK with Voca, the provider of the BACS service, becoming Chairman of VocaLink in 2007. From 2012 to 2015, he served as Chairman of the Audit and Governance Committee of East Kent Hospitals NHS Trust and in 2019 was asked to become Chairman of the Audit and Governance Committee of The Lord’s Taverners, a high-profile charity.
Dr Bernhard Kirschbaum
Former Executive Vice-President of Global Research at Merck Serono
Bernhard Kirschbaum joined the Board in January 2016. Bernhard has over 25 years’ experience in pharmaceutical research and drug development, having held leadership roles at Merck/Merck Serono, Sanofi-Aventis, Aventis and Hoechst Marion Roussel. He has expertise in a broad range of disease areas including oncology, immuno-oncology, immunology, neurological disorders and cardiometabolic diseases. In the eight years to 2013, he worked at Merck/Merck Serono, becoming a member of the Board and Executive Vice-President, Global Research & Early Development. He was responsible for a budget of 1 billion euros and a global team of over 2,500 associates. In his last three years at Merck Serono, he led the successful growth of the company’s R&D portfolio, with over 70 programs, doubling the number of phase II assets in this period. Dr Kirschbaum is currently Chairman of OMEICOS Therapeutics and a board member of BioMedX, Enlivex Therapeutics, Amarna Therapeutics as well as an advisor to the board of KAHR Medical.
Sarah Gordon Wild
Highly experienced industry analyst
Sarah Gordon Wild joined Redx as a Non-Executive Director on 1st July 2020. Sarah brings extensive investment experience in the biotechnology sector to her role at Redx. She currently also serves as a Non-Executive Director of Oxford Nanopore Technologies and Evox Therapeutics, as well as being a Board Member of Lone Pine Capital LLC’s Offshore Funds.
Between 1998-2003 Sarah was Managing Director, Management Committee Member and Senior Healthcare Analyst at Lone Pine Capital LLC. Before this, for over 15 years, Sarah was a senior biotechnology/healthcare analyst on Wall Street at Amerindo Investments Advisors and Hambrecht & Quist and in London at the brokerage firms Kleinwort Grieveson, and Greig Middleton. She graduated from Aberdeen University with a BSc (Hons) in Zoology and with an MSc from Imperial College, London in Social & Economic Aspects of Science and Technology in Industry.
Dr Tom Burt
Investor Director representing Sofinnova Crossover 1 SLP
Thomas (“Tom”) Burt joined Redx as a Non-Executive Director on 4th August 2020. Tom has been a Partner in the Crossover fund at Sofinnova Partners since its inception in 2017. Prior to this, he was a Research Analyst covering UK healthcare and life science equities at Peel Hunt, joining in 2015 after six years as an Investment Director at specialist life science investors; Ares Life Sciences and Novo Holdings. Before this, he spent four years in the Healthcare Investment Banking team at Piper Sandler & Co. Tom holds an Engineering Doctorate from UCL in Biochemical Engineering & Bioprocess Leadership, an MSc in Biochemical Engineering and a BSc in Biotechnology.
Investor Director representing Redmile
Natalie joined Redx as a Non-Executive Director on 19th May 2021 and brings extensive experience in the healthcare sector to the Board. She is a Managing Director focusing on Therapeutics at Redmile, which she joined in 2016. Prior to Redmile, Natalie was a Research Associate at the New York University School of Medicine. Natalie received a BA in Community Health from Brown University and a Certificate in Premedical Sciences from Columbia University.
Dr Rob Scott
Former CMO at Abbvie
Rob Scott joined the Board in January 2022. Rob has over 30 years’ experience in pharmaceutical research and drug development, having held leadership roles at Pfizer, Atherogenics, Cerenis. Amgen and Abbvie. He has expertise in a broad range of disease areas including oncology, cardiology, nephrology, bone & inflammation, immunology, neuroscience, infectious disease and general medicine. Rob recently retired as the Chief Medical Officer at Abbvie where he had responsibility for around 40 new molecular entities, 4500 people and an annual budget of close to $3bn.
Rob is a leader in digital transformation of clinical research including a broad range of aspects from predictive analytics, innovative program and study design, synthetic and historical controls, pragmatic and real world studies, use of passive data collection using IoT and wearables and risk-based monitoring to name a few. He is currently on the board of ArisGlobal, Draupnir Bio and Confo Therapeutics and the scientific advisory boards of Variant Bio, Morningside Biopharma and BioEthics International. Rob is a paid Mentor to an EVP head of R&D at a midsize pharma and an SVP at a big pharma.